Medsider Radio: Learn from Medical Device and Medtech Thought Leaders show

Medsider Radio: Learn from Medical Device and Medtech Thought Leaders

Summary: The goal of Medsider is simple: Help ambitious doers learn from experienced medical device and medtech thought leaders through uncut and unedited interviews.

Join Now to Subscribe to this Podcast

Podcasts:

 The Importance of Having Investors as Customers: Interview with Eric Stone, CEO of Velano Vascular | File Type: audio/mpeg | Duration: 3010

Eric Stone cofounded Velano Vascular with Dr. Pitou Devgon, an internal medicine physician. Velano's first device, PIVO, enables needle-free blood draws directly from peripheral IV catheters. Velano Vascular is backed by a series of well-respected investment firms, leading U.S. health systems, and dozens of health industry veterans. Before starting Velano Vascular, Stone most recently served as VP of Sales and Marketing for MolecularHealth. Prior to that, he helped launch the world’s first bioabsorable stent for Abbott while working out of their California and Belgium offices. He was also a founding member of Model N’s Life Sciences division and began his career in software marketing with Trilogy. Eric also holds advanced degrees in Business Administration and Education from the Wharton School and Harvard University, respectively. He earned a BA degree in English and Psychology from the University of Pennsylvania. Interview Highlights with Eric Stone - Why Eric has been referred to as the “Steve Jobs of drawing blood”.- How PIVO compares to the current standard of care for blood draws.- What brought Eric into healthcare after starting his career in software marketing.- Why Eric pursued both an MBA and Masters in Education and how both degrees have benefited him both personally and professionally.- The biggest lessons Eric learned while launching the first bioabsorbable stent with Abbott.- How Eric first connected with Dr. Devgon and the origin story for the PIVO device.- The four milestones Eric and his team accomplished in taking the PIVO device from initial idea to commercial prototype.- Eric’s approach to garnering financial support from healthcare systems and raising money for Velano Vascular.- How the PIVO device fits into the value-based healthcare equation.- Eric’s favorite business book, the CEO he admires most, and what he’d tell his 25-year-old self.This Is What You Can Do Next 1) Listen to the interview with Eric Stone right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post The Importance of Having Investors as Customers: Interview with Eric Stone, CEO of Velano Vascular appeared first on Medsider.

 The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK | File Type: audio/mpeg | Duration: Unknown

Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the DaVinci robot. Since incorporating Device Access UK in 2010, Michael and his team have helped over 180 medical device and diagnostic companies navigate their way into the NHS. Their clients range from small start-ups to large multinationals from across the world. In 2014, Device Access was granted a commercial license from NHS England to access over 750 million pseudonymous patient health records. This data allows Device Access to examine diagnosis, procedure, and spend data nationally by NHS hospitals, and in turn enables them to do 3 things: - See how their client’s technology could affect the current patient pathway. - Assist in building a value story with the National Institute for Health and Care Excellence (NICE). - Develop a solid business case for local and national NHS Hospital adoption. Interview Highlights with Michael Branagan-Harris - What has changed since my last interview with Mike 4-5 years ago, especially as it pertains to the NHS, NICE, and the National Innovation Center (NIC). - The current and significant need for medtech innovation in the UK. - The biggest mistakes medtech companies make when commercializing in Europe. - The ideal process medical device companies should follow when launching their devices in the UK, including Mike’s PICO framework and Connect4 methodology. - Mike’s thoughts on Brexit and what it means for medtech in the UK. This Is What You Can Do Next 1) Listen to the interview with Michael Branagan-Harris right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK appeared first on Medsider.

 The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK | File Type: audio/mpeg | Duration: 2480

Michael Branagan-Harris is the CEO of Device Access UK and has been involved in the marketing of medical devices to the National Health Service (NHS) for the last 27 years. Products he’s commercialized range from simple wound dressings to the introduction of the Lap Band for obesity, endovascular graft repair, endo laparoscopic surgery, and the DaVinci robot. Since incorporating Device Access UK in 2010, Michael and his team have helped over 180 medical device and diagnostic companies navigate their way into the NHS. Their clients range from small start-ups to large multinationals from across the world. In 2014, Device Access was granted a commercial license from NHS England to access over 750 million pseudonymous patient health records. This data allows Device Access to examine diagnosis, procedure, and spend data nationally by NHS hospitals, and in turn enables them to do 3 things: - See how their client’s technology could affect the current patient pathway.- Assist in building a value story with the National Institute for Health and Care Excellence (NICE).- Develop a solid business case for local and national NHS Hospital adoption.Interview Highlights with Michael Branagan-Harris - What has changed since my last interview with Mike 4-5 years ago, especially as it pertains to the NHS, NICE, and the National Innovation Center (NIC).- The current and significant need for medtech innovation in the UK.- The biggest mistakes medtech companies make when commercializing in Europe.- The ideal process medical device companies should follow when launching their devices in the UK, including Mike’s PICO framework and Connect4 methodology.- Mike’s thoughts on Brexit and what it means for medtech in the UK.This Is What You Can Do Next 1) Listen to the interview with Michael Branagan-Harris right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post The Biggest Mistakes Medical Device Companies Make When Commercializing in Europe: Interview with Michael Branagan-Harris, CEO of Device Access UK appeared first on Medsider.

 Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular | File Type: audio/mpeg | Duration: Unknown

Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Before that, he served as President of Abiomed, where he successfully obtained a PMA approval for the first, FDA-approved ventricular assist device. Bruce developed cardiac pacing and anti-arrhythmia products at Cordis Corporation as well. Bruce holds advanced degrees in Biomedical Engineering from Columbia University and Business Administration from the MIT Sloan School of Management. He earned a B.S. degree in Chemical Engineering from Penn State University. Interview Highlights with Bruce Shook - After a storied medtech career, the device that Bruce is most proud of. - The origin story for the Tack Endovascular System and how it’s different than current peripheral vascular stents. - Bruce’s transition from Cordis to Abiomed and what he learned both personally and professionally. - Why Bruce decided to pursue an MBA from MIT after his run with Abiomed. - How Bruce and his team at Neuron Therapeutics responded after their failed clinical trial. - The lessons Bruce learned while trying to gain insurance coverage and reimbursement for the TMS device with Neuronetics. - Bruce’s advice for other medtech entrepreneurs that need to raise money beyond the “friends and family” round. - Bruce’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self. This Is What You Can Do Next 1) Listen to the interview with Bruce Shook right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular appeared first on Medsider.

 Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular | File Type: audio/mpeg | Duration: 2549

Bruce Shook joined Intact Vascular in 2014 as President and CEO. A highly-experienced, medical device executive with more than 30 years of industry experience, Bruce was previously Co-founder, Director, President, and CEO of Neuronetics, which is a privately held medical device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Shook was Co-founder, Director, President, and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders. Before that, he served as President of Abiomed, where he successfully obtained a PMA approval for the first, FDA-approved ventricular assist device. Bruce developed cardiac pacing and anti-arrhythmia products at Cordis Corporation as well. Bruce holds advanced degrees in Biomedical Engineering from Columbia University and Business Administration from the MIT Sloan School of Management. He earned a B.S. degree in Chemical Engineering from Penn State University. Interview Highlights with Bruce Shook - After a storied medtech career, the device that Bruce is most proud of.- The origin story for the Tack Endovascular System and how it’s different than current peripheral vascular stents.- Bruce’s transition from Cordis to Abiomed and what he learned both personally and professionally.- Why Bruce decided to pursue an MBA from MIT after his run with Abiomed.- How Bruce and his team at Neuron Therapeutics responded after their failed clinical trial.- The lessons Bruce learned while trying to gain insurance coverage and reimbursement for the TMS device with Neuronetics.- Bruce’s advice for other medtech entrepreneurs that need to raise money beyond the “friends and family” round.- Bruce’s favorite business book, the CEO he most admires, and the advice he’d give to his 25-year-old self.This Is What You Can Do Next 1) Listen to the interview with Bruce Shook right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post Conquering the Coverage and Reimbursement Landscape: Interview with Bruce Shook, President of Intact Vascular appeared first on Medsider.

 How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical | File Type: audio/mpeg | Duration: Unknown

Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a medical consultant and scientific advisory board member for a host of medical device companies including Boston Scientific, Cook Medical, Endotronics, Novate Medical, Crocks Biomedical, Endoshape, the Medicines Company, and Varian Medical. Dr. Smouse has been involved in more than 30 international and national clinical research trials as the Global, National, and Local Principle Investigator and is the author of nearly 150 scientific publications and presentations. Interview Highlights with Dr. Bob Smouse - The time when Dr. Smouse and his team first believed they had a winner on their hands with the ConvertX System. - How Dr. Smouse and his team built out their first prototype. - His approach to raising money for BrightWater Medical, which involved a partnership with the venture arm of OSF, a large hospital system in the Midwest. - The regulatory pathway that Dr. Smouse followed for the ConvertX System and what he learned through that process. - How Dr. Smouse and his team are approaching value-based healthcare with respect to the ConvertX System. - Smouse's favorite business book, the CEO he most admires, and the advice he'd give to his 30-year-old self. This Is What You Can Do Next 1) Listen to the interview with Dr. Bob Smouse right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical appeared first on Medsider.

 How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical | File Type: audio/mpeg | Duration: 2837

Dr. Bob Smouse has over 20 years of experience in interventional radiology, endovascular surgery and clinical research. In addition to acting as CEO and CMO of BrightWater Medical and teaching at the University of Illinois College of Medicine, he provides interventional medical services to local hospitals through Central Illinois Radiology Associates. Dr. Smouse is a medical consultant and scientific advisory board member for a host of medical device companies including Boston Scientific, Cook Medical, Endotronics, Novate Medical, Crocks Biomedical, Endoshape, the Medicines Company, and Varian Medical. Dr. Smouse has been involved in more than 30 international and national clinical research trials as the Global, National, and Local Principle Investigator and is the author of nearly 150 scientific publications and presentations. Interview Highlights with Dr. Bob Smouse - The time when Dr. Smouse and his team first believed they had a winner on their hands with the ConvertX System.- How Dr. Smouse and his team built out their first prototype.- His approach to raising money for BrightWater Medical, which involved a partnership with the venture arm of OSF, a large hospital system in the Midwest.- The regulatory pathway that Dr. Smouse followed for the ConvertX System and what he learned through that process.- How Dr. Smouse and his team are approaching value-based healthcare with respect to the ConvertX System.- Smouse's favorite business book, the CEO he most admires, and the advice he'd give to his 30-year-old self.This Is What You Can Do Next 1) Listen to the interview with Dr. Bob Smouse right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post How to Go from Physician to Medtech Entrepreneur: Interview with Dr. Bob Smouse, CEO of BrightWater Medical appeared first on Medsider.

 Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular | File Type: audio/mpeg | Duration: Unknown

More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of the heart muscle. At that time, Dr. Johnson had been working on a prototype device to listen to heart sounds as a part of her doctoral degree. Her husband’s coronary artery disease had been present, but went silent and undetected. Inspired and motivated by her loss, Dr. Johnson decided to apply the principles of frequency analysis to create an acoustic device to identify obstructive coronary artery disease, which is now called the CADence System. Marie has a Ph.D. in Biomedical Engineering and as the Founder of AUM Cardiovascular, she’s successfully raised over $10 million in angel investment from individual investors, small funds, and physicians.  Before becoming CEO of AUM, Dr. Johnson designed and launched the University of Minnesota Medical Devices Innovation Fellowship Program. Interview Highlights with Dr. Marie Johnson - The time when Dr. Johnson realized she had a “winner” on her hands with the CADense System. - The origin story of the CADense System. - How Dr. Johnson went from initial idea, to prototype, to eventual production. - What she has learned raising money from a wide variety of investors. - In an era of consumer-centric wearables, how Dr. Johnson landed on a business model for the CADense System. - Her approach to managing clinical trials with a small team. - The biggest lessons Dr. Johnson has learned through the process of building AUM Cardiovascular form scratch. - Johnson’s favorite business book, the CEO that most inspires her, and the advice she’d give to her 25-year old self. This Is What You Can Do Next 1) Listen to the interview with Dr. Marie Johnson right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular appeared first on Medsider.

 Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular | File Type: audio/mpeg | Duration: 2452

More than a decade ago, AUM Cardiovascular founder Dr. Marie Johnson was a doctoral student when tragedy struck her and her family. Her husband, Rob, passed away suddenly at the age of 41. He had blockages in his coronary arteries including a ruptured plaque in the left anterior descending artery supplying a large part of the heart muscle. At that time, Dr. Johnson had been working on a prototype device to listen to heart sounds as a part of her doctoral degree. Her husband’s coronary artery disease had been present, but went silent and undetected. Inspired and motivated by her loss, Dr. Johnson decided to apply the principles of frequency analysis to create an acoustic device to identify obstructive coronary artery disease, which is now called the CADence System. Marie has a Ph.D. in Biomedical Engineering and as the Founder of AUM Cardiovascular, she’s successfully raised over $10 million in angel investment from individual investors, small funds, and physicians. Before becoming CEO of AUM, Dr. Johnson designed and launched the University of Minnesota Medical Devices Innovation Fellowship Program. Interview Highlights with Dr. Marie Johnson - The time when Dr. Johnson realized she had a “winner” on her hands with the CADense System.- The origin story of the CADense System.- How Dr. Johnson went from initial idea, to prototype, to eventual production.- What she has learned raising money from a wide variety of investors.- In an era of consumer-centric wearables, how Dr. Johnson landed on a business model for the CADense System.- Her approach to managing clinical trials with a small team.- The biggest lessons Dr. Johnson has learned through the process of building AUM Cardiovascular form scratch.- Johnson’s favorite business book, the CEO that most inspires her, and the advice she’d give to her 25-year old self.This Is What You Can Do Next 1) Listen to the interview with Dr. Marie Johnson right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post Managing a Clinical Trial with a Small Team and Lessons Learned Raising Money for an Early Stage Medtech Startup: Interview with Dr. Marie Johnson, Founder of AUM Cardiovascular appeared first on Medsider.

 The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx | File Type: audio/mpeg | Duration: Unknown

Shaun Bagai is the CEO of RenovoRx.  He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most recently, Shaun led global market development for HeartFlow, which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader (KOL) development, ultimately resulting in a company investment to form HeartFlow-Japan. Interview Highlights with Shaun Bagai - Shaun’s reaction to Medtronic’s acquisition of Ardian back in 2011. - The power of mentorship and networking and their impact on Shaun’s career. - How Shaun landed in medtech with TransVascular before it was purchased by Medtronic in the early 2000’s. - How Shaun’s experience in a field-based sales capacity has helped him throughout his career. - Shaun’s transition from Medtronic to Ardian and the biggest challenges he faced while developing the market for renal denervation. - Shaun’s cross-functional experiences while helping to build HeartFlow-Japan. - What Shaun and his team are building at RenovoRx and what lies ahead for the company. - Shaun’s favorite business book, the CEO that inspires him, and what he would tell his 25-year old self. This Is What You Can Do Next 1) Listen to the interview with Shaun Bagai right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx appeared first on Medsider.

 The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx | File Type: audio/mpeg | Duration: 2581

Shaun Bagai is the CEO of RenovoRx. He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. He was instrumental in developing the European market for renal denervation, which led to the acquisition of the first renal denervation company, Ardian, by Medtronic in 2011. Most recently, Shaun led global market development for HeartFlow, which included directing Japanese market research, regulatory/payer collaboration, and Key Opinion Leader (KOL) development, ultimately resulting in a company investment to form HeartFlow-Japan. Interview Highlights with Shaun Bagai - Shaun’s reaction to Medtronic’s acquisition of Ardian back in 2011.- The power of mentorship and networking and their impact on Shaun’s career.- How Shaun landed in medtech with TransVascular before it was purchased by Medtronic in the early 2000’s.- How Shaun’s experience in a field-based sales capacity has helped him throughout his career.- Shaun’s transition from Medtronic to Ardian and the biggest challenges he faced while developing the market for renal denervation.- Shaun’s cross-functional experiences while helping to build HeartFlow-Japan.- What Shaun and his team are building at RenovoRx and what lies ahead for the company.- Shaun’s favorite business book, the CEO that inspires him, and what he would tell his 25-year old self.This Is What You Can Do Next 1) Listen to the interview with Shaun Bagai right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post The Power of Networking in Medtech, Challenges in Developing the Renal Denervation Market, and the Value of Cross-Functional Experience: Interview with Shaun Bagai, CEO of RenovoRx appeared first on Medsider.

 The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens | File Type: audio/mpeg | Duration: Unknown

Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson & Johnson from early 2010 through early 2012 as Worldwide President of their ENT Division. Facteau joined Johnson & Johnson via the $800M dollar acquisition of Acclarent where he served as President, CEO, and a member of the Board of Directors since the company’s formation in 2004. Under Bill’s leadership, the Acclarent went from concept to acquisition in 5 ½ years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable. Prior to joining Acclarent, Bill was the General Manager of the Endovascular Division at Abbott Vascular where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. He joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was Sales Director. From July 1993 to April 1998, Bill worked in a number of sales and sales management positions at United States Surgical Corporation, or otherwise known as US Surgical. Interview Highlights with Bill Facteau - How Bill and his team celebrated after Acclarent was acquired by Johnson & Johnson. - Bill’s current role at Earlens, the technology they’ve developed, and how they intend to commercialize it. - What brought Bill into the medical device space with U.S. Surgical back in the early 1990's. - How Bill’s medtech sales experience has impacted the rest of his career. - What medtech entrepreneurs can learn from Bill’s experience helping to build Acclarent from the ground floor. - Why Bill didn’t want to stay in venture capital after spending time at ExploraMed and NEA after J&J's acquisition of Acclarent. - Mindshare and comfort zones: Bill’s advice on how to experience personal growth as a leader in medtech. - People, product, opportunity: what they mean to Bill as a medtech executive. - Bill's thoughts on the regulatory and reimbursement environments and why he loves the direct-to-patient approach they are taking at Earlens. - Bill’s favorite business book, the CEO he admires most, and what he would tell his 25-year old self. This Is What You Can Do Next 1) Listen to the interview with Bill Facteau right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. The post The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens appeared first on Medsider.

 The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens | File Type: audio/mpeg | Duration: 2693

Bill Facteau joined Earlens Corporation as Chairman, President, and CEO in November of 2013. Most recently, he was the Vice Chairman of ExploraMed, a medical device incubator based on the West Coast and an Entrepreneur in Residence at New Enterprise Associates. Previously, Bill was at Johnson & Johnson from early 2010 through early 2012 as Worldwide President of their ENT Division. Facteau joined Johnson & Johnson via the $800M dollar acquisition of Acclarent where he served as President, CEO, and a member of the Board of Directors since the company’s formation in 2004. Under Bill’s leadership, the Acclarent went from concept to acquisition in 5 ½ years, raised over $100M, created jobs for approximately 400 employees, grew revenues to $100M and became profitable. Prior to joining Acclarent, Bill was the General Manager of the Endovascular Division at Abbott Vascular where he served as a member of the executive team and created the entry strategy for Abbott to participate in the peripheral vascular space. He joined Abbott Laboratories via the $683 million acquisition of Perclose, a vessel closure company, where he was Sales Director. From July 1993 to April 1998, Bill worked in a number of sales and sales management positions at United States Surgical Corporation, or otherwise known as US Surgical. Interview Highlights with Bill Facteau - How Bill and his team celebrated after Acclarent was acquired by Johnson & Johnson.- Bill’s current role at Earlens, the technology they’ve developed, and how they intend to commercialize it.- What brought Bill into the medical device space with U.S. Surgical back in the early 1990's.- How Bill’s medtech sales experience has impacted the rest of his career.- What medtech entrepreneurs can learn from Bill’s experience helping to build Acclarent from the ground floor.- Why Bill didn’t want to stay in venture capital after spending time at ExploraMed and NEA after J&J's acquisition of Acclarent.- Mindshare and comfort zones: Bill’s advice on how to experience personal growth as a leader in medtech.- People, product, opportunity: what they mean to Bill as a medtech executive.- Bill's thoughts on the regulatory and reimbursement environments and why he loves the direct-to-patient approach they are taking at Earlens.- Bill’s favorite business book, the CEO he admires most, and what he would tell his 25-year old self.This Is What You Can Do Next 1) Listen to the interview with Bill Facteau right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. The post The Importance of Medical Device Sales Experience, the Rocket Ship that was Acclarent, and How to Achieve Personal Growth as a Medtech Leader: Interview with Bill Facteau, President and CEO of Earlens appeared first on Medsider.

 Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger | File Type: audio/mpeg | Duration: 2382

Dr. John Simpson. Even if you’re a medical device newbie, you’ve probably heard of him. He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA). This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career, Dr. Simpson has founded and successfully exited companies like ACS and DVI (both acquired by Eli Lily), CVIS (acquired by Boston Scientific), Perclose (sold to Abbott), Lumend (acquired by Cordis), Fox Hollow (acquired by ev3 which now part of Medtronic). It’s borderline exhausting just thinking about all of these companies, let alone starting them! Plain and simple, Dr. Simpson is a legend in the space and he isn’t done yet. He currently serves as the Executive Chairman of Avinger, where he and his team are developing a portfolio of unique cardiovascular products aimed at solving the challenging space of peripheral artery disease. In this interview with Dr. Simpson, we learn about the key lessons he’s learned throughout his historic medtech career and why he’s still fired up about medical device innovation after all these years. Interview Highlights with Dr. John Simpson - How Dr. Simpson's infamous encounter with Jack Nicklaus (yes, that Jack Nicklaus) led to his firing as a bank teller, which forced him down a new career path.- What initially attracted Dr. Simpson to the field of cardiology and how treating vascular disease has been a consistent theme throughout all of the companies he’s started.- The reasons why Dr. Simpson decided to pursue Andreas Gruentzig's balloon catheter technologies and how it led to his own inventions.- As a medtech entrepreneur, why knowing your strengths and limitations is key to making a difference in the lives of others.- Discover Dr. Simpson's approach to building a team, and how surrounding himself with people that have a broad group of skill sets has enabled his success throughout the years.- The key challenges Dr. Simpson has faced with his new company, Avinger, and the important lessons he’s learned.- Simpson reveals his approach to raising capital in the medtech industry, and how persevering through challenges has been crucial for Avinger's success.- The advice Dr. Simpson would give to his 30-year-old self, and how endurance through criticism is what ultimately leads to revolution within the medical field.This Is What You Can Do Next 1) Listen to the interview with Dr. John Simpson right now: 2) You can also download the mp3 file of the interview by clicking here Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes. And if you get a chance, leave us an honest rating and review. About Dr. John Simpson Dr. John Simpson received his PhD in Immunology from the University of Texas and his MD from Duke University. He completed his fellowship in interventional cardiology at Stanford University. Dr. Simpson is a member of the American College of Physicians and a fellow of the American College of Cardiology. He has published extensively on a wide variety of subjects and lectured throughout the world. Dr. Simpson has started several companies dedicated to providing patients with the most cutting-edge therapies in a variety of different areas. He invented and commercialized the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA). This single idea created the field of interventional cardiology as we know it today. He currently serves as Executive Chairman of Avinger. The post Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger appeared first on Medsider.

 Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger | File Type: audio/mpeg | Duration: Unknown

Dr. John Simpson.  Even if you’re a medical device newbie, you’ve probably heard of him.  He’s credited with inventing and commercializing the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This single idea created the field of interventional cardiology as we know it today. Over the course of his renowned medtech career, Dr. Simpson has founded and successfully exited companies like ACS and DVI (both acquired by Eli Lily), CVIS (acquired by Boston Scientific), Perclose (sold to Abbott), Lumend (acquired by Cordis), Fox Hollow (acquired by ev3 which now part of Medtronic).  It’s borderline exhausting just thinking about all of these companies, let alone starting them! Plain and simple, Dr. Simpson is a legend in the space and he isn’t done yet.  He currently serves as the Executive Chairman of Avinger, where he and his team are developing a portfolio of unique cardiovascular products aimed at solving the challenging space of peripheral artery disease. In this interview with Dr. Simpson, we learn about the key lessons he’s learned throughout his historic medtech career and why he’s still fired up about medical device innovation after all these years. Interview Highlights with Dr. John Simpson - How Dr. Simpson's infamous encounter with Jack Nicklaus (yes, that Jack Nicklaus) led to his firing as a bank teller, which forced him down a new career path. - What initially attracted Dr. Simpson to the field of cardiology and how treating vascular disease has been a consistent theme throughout all of the companies he’s started. - The reasons why Dr. Simpson decided to pursue Andreas Gruentzig's balloon catheter technologies and how it led to his own inventions. - As a medtech entrepreneur, why knowing your strengths and limitations is key to making a difference in the lives of others. - Discover Dr. Simpson's approach to building a team, and how surrounding himself with people that have a broad group of skill sets has enabled his success throughout the years. - The key challenges Dr. Simpson has faced with his new company, Avinger, and the important lessons he’s learned. - Simpson reveals his approach to raising capital in the medtech industry, and how persevering through challenges has been crucial for Avinger's success. - The advice Dr. Simpson would give to his 30-year-old self, and how endurance through criticism is what ultimately leads to revolution within the medical field. This Is What You Can Do Next 1) Listen to the interview with Dr. John Simpson right now: 2) You can also download the mp3 file of the interview by clicking here. Don't forget – you can listen to this interview and all of the other Medsider interviews via iTunes.  And if you get a chance, leave us an honest rating and review. About Dr. John Simpson Dr. John Simpson received his PhD in Immunology from the University of Texas and his MD from Duke University.  He completed his fellowship in interventional cardiology at Stanford University.  Dr. Simpson is a member of the American College of Physicians and a fellow of the American College of Cardiology. He has published extensively on a wide variety of subjects and lectured throughout the world. Dr. Simpson has started several companies dedicated to providing patients with the most cutting-edge therapies in a variety of different areas. He invented and commercialized the first over-the-wire balloon catheter used for percutaneous transluminal coronary angioplasty (PTCA).  This single idea created the field of interventional cardiology as we know it today.  He currently serves as Executive Chairman of Avinger. The post Why Curiosity and Persistence are Crucial Characteristics for Medtech Entrepreneurs: Interview with the Legendary Dr. John Simpson, Executive Chairman of Avinger appeared first on Medsider.

Comments

Login or signup comment.